Search results
Results from the WOW.Com Content Network
Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. [10] [4] It is used as a method of birth control and as a part of menopausal hormone therapy.
150 mg/day or 200 mg twice daily Finasteride: Propecia: 5αR inhibitor: Oral: 1–5 mg/day Dutasteride: Avodart: 5αR inhibitor: Oral: 0.25–0.5 mg/day Progesterone: Prometrium [c] Progestogen: Oral: 100–400 mg/day Medroxyprogesterone acetate: Provera: Progestogen: Oral: 2.5–40 mg/day Depo-Provera: Progestogen: IM: 150 mg every 3 mos: Depo ...
Provera [c] PO, IM, SC: ... They are used questionably for treatment of recurrent pregnancy loss and for prevention of preterm birth in ... (10 mg/day for 18–20 ...
Medroxyprogesterone acetate (Amen, Curretab, Cycrin, Provera) – 2.5 mg, 5 mg, 10 mg; Megestrol acetate (Megace) – 20 mg, 40 mg – approved specifically for the treatment of breast and endometrial cancer [46] and for the treatment of anorexia, cachexia, and weight loss in patients with AIDS Tooltip acquired immunodeficiency syndrome [47]
Hormonal therapies to reduce or stop menstrual bleeding have long been used to manage a number of gynecologic conditions including menstrual cramps (dysmenorrhea), heavy menstrual bleeding, irregular or other abnormal uterine bleeding, menstrual-related mood changes (premenstrual syndrome or premenstrual dysphoric disorder), and pelvic pain due to endometriosis or uterine fibroids.
100–400 mg/day Medroxyprogesterone acetate: Provera: Progestogen: Oral: 2.5–40 mg/day Depo-Provera: Progestogen: IM: 150 mg every 3 mos: Depo-SubQ Provera 104: Progestogen: SC: 104 mg every 3 mos Hydroxyprogesterone caproate: Proluton: Progestogen: IM: 250 mg/wk Dydrogesterone: Duphaston: Progestogen: Oral: 20 mg/day Drospirenone: Slynd ...
Pfizer CEO is no stranger to risks, and hopes to repeat the company's COVID-19 success with an oral treatment. Pfizer authorizes $1 billion for oral COVID-19 treatment, CEO says [Video] Skip to ...
The treatment choices of those referred to hospital in the UK for heavy menstrual bleeding. [20] The first line treatment option for those with HMB and no identified pathology, fibroids less than 3 cm in diameter, and/or suspected or confirmed adenomyosis is the levonorgestrel-releasing intrauterine system (LNG-IUS). [16]